These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 30016177)

  • 1. Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results.
    Dantal J; Morelon E; Rostaing L; Goffin E; Brocard A; Tromme I; Broeders N; Del Marmol V; Chatelet V; Dompmartin A; Kessler M; Serra A; Hofbauer GFL; Kamar N; Pouteil-Noble C; Kanitakis J; Roux A; Decullier E; Euvrard S;
    J Clin Oncol; 2018 Sep; 36(25):2612-2620. PubMed ID: 30016177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sirolimus and secondary skin-cancer prevention in kidney transplantation.
    Euvrard S; Morelon E; Rostaing L; Goffin E; Brocard A; Tromme I; Broeders N; del Marmol V; Chatelet V; Dompmartin A; Kessler M; Serra AL; Hofbauer GF; Pouteil-Noble C; Campistol JM; Kanitakis J; Roux AS; Decullier E; Dantal J;
    N Engl J Med; 2012 Jul; 367(4):329-39. PubMed ID: 22830463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients.
    Murray SL; Daly FE; O'Kelly P; O'Leary E; Deady S; O'Neill JP; Dudley A; Rutledge NR; McCormick A; Houlihan DD; Williams Y; Morris PG; Ni Raghallaigh S; Moloney FJ; Sexton DJ; Conlon PJ
    Ren Fail; 2020 Nov; 42(1):607-612. PubMed ID: 32605413
    [No Abstract]   [Full Text] [Related]  

  • 4. Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients.
    van den Akker JM; Wetzels JF; Hoitsma AJ
    Kidney Int; 2006 Oct; 70(7):1355-7. PubMed ID: 16912706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus.
    Hoogendijk-van den Akker JM; Harden PN; Hoitsma AJ; Proby CM; Wolterbeek R; Bouwes Bavinck JN; de Fijter JW
    J Clin Oncol; 2013 Apr; 31(10):1317-23. PubMed ID: 23358973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients.
    Alter M; Satzger I; Schrem H; Kaltenborn A; Kapp A; Gutzmer R
    J Dtsch Dermatol Ges; 2014 Jun; 12(6):480-8. PubMed ID: 24813579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
    Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial.
    Alberú J; Pascoe MD; Campistol JM; Schena FP; Rial Mdel C; Polinsky M; Neylan JF; Korth-Bradley J; Goldberg-Alberts R; Maller ES;
    Transplantation; 2011 Aug; 92(3):303-10. PubMed ID: 21792049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer.
    Campbell SB; Walker R; Tai SS; Jiang Q; Russ GR
    Am J Transplant; 2012 May; 12(5):1146-56. PubMed ID: 22420843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus and non-melanoma skin cancer prevention after kidney transplantation: a meta-analysis.
    Gu YH; Du JX; Ma ML
    Asian Pac J Cancer Prev; 2012; 13(9):4335-9. PubMed ID: 23167339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
    Flechner SM; Goldfarb D; Solez K; Modlin CS; Mastroianni B; Savas K; Babineau D; Kurian S; Salomon D; Novick AC; Cook DJ
    Transplantation; 2007 Apr; 83(7):883-92. PubMed ID: 17460558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirolimus and skin-cancer prevention in kidney transplantation.
    Smak Gregoor PJ
    N Engl J Med; 2012 Oct; 367(16):1565; author reply 1565-6. PubMed ID: 23075186
    [No Abstract]   [Full Text] [Related]  

  • 13. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure.
    Groetzner J; Kaczmarek I; Schulz U; Stegemann E; Kaiser K; Wittwer T; Schirmer J; Voss M; Strauch J; Wahlers T; Sohn HY; Wagner F; Tenderich G; Stempfle HU; Mueller-Ehmsen J; Schmid C; Vogeser M; Koch KC; Reichenspurner H; Daebritz S; Meiser B; Reichart B;
    Transplantation; 2009 Mar; 87(5):726-33. PubMed ID: 19295318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of sirolimus as an adjuvant therapy for kidney transplant recipients with high-risk cutaneous squamous cell carcinomas: a prospective non-randomized controlled study.
    Fázio MR; Cristelli MP; Tomimori J; Koga CE; Ogawa MM; Beneventi GT; Tedesco-Silva H; Medina-Pestana J
    J Bras Nefrol; 2023; 45(4):480-487. PubMed ID: 37565728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of everolimus on skin cancers in calcineurin inhihitor-treated heart transplant recipients.
    Euvrard S; Boissonnat P; Roussoulières A; Kanitakis J; Decullier E; Claudy A; Sebbag L
    Transpl Int; 2010 Aug; 23(8):855-7. PubMed ID: 19951373
    [No Abstract]   [Full Text] [Related]  

  • 16. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
    Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
    Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of sirolimus in the prevention of cutaneous squamous cell carcinoma in organ transplant recipients.
    Leblanc KG; Hughes MP; Sheehan DJ
    Dermatol Surg; 2011 Jun; 37(6):744-9. PubMed ID: 21605234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous squamous cell carcinomas in solid organ transplant recipients: emerging strategies for surveillance, staging, and treatment.
    Kim C; Cheng J; Colegio OR
    Semin Oncol; 2016 Jun; 43(3):390-4. PubMed ID: 27178693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion from calcineurin inhibitors to sirolimus reduces vascularization and thickness of post-transplant cutaneous squamous cell carcinomas.
    Rival-Tringali AL; Euvrard S; Decullier E; Claudy A; Faure M; Kanitakis J
    Anticancer Res; 2009 Jun; 29(6):1927-32. PubMed ID: 19528449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
    Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
    Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.